
    
      This is a non-inferiority trial. The primary outcome is the percentage of subjects achieving
      ACR20. According to the global instruction of Remicade, the effective rate of Remicade is
      50%, and the placebo is 20%. Calculate the critical value δ=（50%-20%）×50%=15%, one-side
      α=0.025, β=0.20, experimental group : control group = 1:1, the results are: CMAB008 group 175
      participants, control group 175 participants, 350 participants in total. Take 10% drop-out
      into consideration, the finial sample sizes are: CMAB008 group 196 participants, control
      group 196 participants, 392 participants in total.

      During the entire duration of the study, all adverse events (AE) and all serious adverse
      events (SAEs) are collected, fully investigated and documented in source documents and case
      report forms (CRF). Study duration encompassed the time from when the participant sign the
      informed consent until the last protocol-specific procedure has been completed, including a
      safety follow up period.

      This study will be conducted in compliance with the protocol, the current version of the
      Declaration of Helsinki, the guidelines of Good Clinical Practice (GCP) as well as all
      national legal and regulatory requirements.
    
  